1. Introduction {#sec1}
===============

*Toxoplasma gondii*is one of the most prevalent obligate intracellular protozoan parasites of man and livestock \[[@B1]--[@B5]\]. Feline species are definitive hosts for *Toxoplasma gondii* and a wide range of animals serve as intermediate hosts. Globally, it is estimated that about one-third of the population is infected with *T. gondii* \[[@B3]\]. Although *T. gondii* infection in immune-competent individuals is usually asymptomatic or causes a mild flu-like illness \[[@B4]\], it may become severe and can occasionally be fatal in immune-compromised people, such as AIDS patients or pregnant women \[[@B2], [@B6]\]. *Toxoplasma gondii* infection in AIDS patients and pregnant women causes severe encephalitis, and neurologic diseases, and can affect the heart, liver, inner ears, and eyes (chorioretinitis) \[[@B2]\]. Infection with *T. gondii* during pregnancy can result in spontaneous abortion, still-birth, fetal death, neonatal death, or various congenital defects, such as hydrocephalus, central nervous system abnormalities, and chorioretinitis \[[@B7]\]. HIV infected individuals are at risk of acute toxoplasmosis due to reactivation of *T. gondii*. It also causes cervical lymphadenopathy or ocular disease in HIV infected immune competent individuals.

Humans get infections with *T. gondii* after ingesting raw or undercooked meat, by ingesting cat-shed oocysts via contaminated soil, food or water; or trans-placental transmission \[[@B3]--[@B4], [@B5]\].

Serological methods used for *T. gondii* diagnosis such as enzyme-linked immunesorbent assay (ELISA) and indirect immunofluorescence assay (IFA) are considered as gold standard for the detection of *Toxoplasma*-specific antibodies (IgG or IgM) \[[@B4]\].

In Ethiopia, human toxoplasmosis infection is a neglected disease \[[@B7]\]. The prevalence of *T. gondii* infection in Ethiopia has been reported in some populations; mainly in HIV infected individuals, pregnant women, child bearing age women, and in general population \[[@B4]\].

For appropriate diagnosis, treatment, and control of *T. gondii* infections, information about the seroprevalence of toxoplasmosis in different special populations is very important. So, this systematic review of the literature aimed to evaluate the sero-prevalence of *T. gondii* among pregnant women and HIV/AIDS patients in Ethiopia.

2. Methods {#sec2}
==========

2.1. Literature Search and Data Extraction {#sec2.1}
------------------------------------------

Relevant literatures were searched on Pubmed, Pubmed central, Google scholar, science direct databases, Scopus, theses of Ethiopian medical universities, and Ethiopian journals such as Ethiopia journal of health development and proceedings of professional associations from May, 2018 to June, 2018. Full-length articles and abstracts were collected using keywords such as *Toxoplasma gondii*, Toxoplasmosis, pregnant women, HIV/AIDS, and Ethiopia. These key words were also used in combination using boolean operators. Overlapped articles found in more than one databases were excluded. Annual research conferences and preceding of Ethiopian medical laboratory association (EMLA), and Ethiopian public health laboratory associations\' (EPHLAs) records were reviewed to identify relevant unpublished articles.

The reference lists of published studies included in this meta-analysis were searched for additional articles. Two authors independently reviewed all collected studies for eligibility and they extracted the required information based on the objective this meta-analysis.

2.2. Data Collection {#sec2.2}
--------------------

Pre-designed data extraction form was developed by authors based on the objective of this review. Studies conducted in Ethiopia to estimate the sero-prevalence of *T. gondii* infection in pregnant women and HIV/AIDS patients were included. All collected studies were assessed by two authors for eligibility to be included in this review. In case of disagreement on the eligibility of identified studies, authors held discussion to resolve the issue by considering the quality of identified study and the aim of the present review. Studies performed in study groups other than pregnant women, and HIV/AIDS and those studies that did not use random sampling methods as a sampling technique were excluded ([Figure 1](#fig1){ref-type="fig"}). Information about year of publication, first author, study area, study design, total sample size, number of sero-positive individuals, and laboratory methods used for *T. gondii* diagnoses was carefully investigated.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Point estimates and 95% confidence intervals of seroprevalence of all included studies were calculated. An overall seroprevalence and group-specific sero-prevalences were calculated among HIV/AIDS patients and pregnant women. Heterogeneity among studies was visualized using a forest plot chart. The *I*^2^ and Cochran\'s Q tests were used to quantify the variations between studies. The heterogeneity was considered not significant when *P* \> 0.1 and *I*^2^ \< 50%. Due to the heterogeneity of studies included in this meta-analysis, random effect model was used by considering the included studies used random samples from a population. This meta-analysis was performed using the trial version of StatsDirect statistical software (<https://statsdirect.com>).

3. Results {#sec3}
==========

Out of 65 studies from literature searches using key words, 17 studies were eligible and included in the present systematic review and meta-analysis. Eight studies described the sero-prevalence of *T. gondii* in pregnant women, whereas 8 studies reported *T. gondii* infection in HIV/AIDS patients. There was also one study which reported seroprevalence of *T. gondii* in HIV/AIDS patients and pregnant women. This study was considered in both pregnant women and HIV/AIDS patient groups during analysis. The study designs of all eligible and included studies were cross-sectional. In this review, Enzyme-linked immunosorbent assay (ELISA) and latex agglutination slide tests were the commonly used methods for the detection of *T. gondii* antibodies. The higher sero-prevalence of *T. gondii* (96.7% and 93.6%) was reported in HIV/AIDS patients from Mizan Aman Hospital and selected areas of Ethiopia, respectively. On the other hand the lower seroprevalence (18.5% and 34.9%) reported in this study was in pregnant women from Felege Hiwot Hospital from Jigjiga Hospital (Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}).

Detection of *T. gondii* IgG and IgM is one of the commonest serologic diagnoses. IgG detection indicates either past or present infection while the detection of IgM showed early infection of *T. gondii*. Based on IgG assessment, most of the current reviewed studies reported above 95% *T. gondii* IgG sero-prevalence. In general, the sero-prevalence of IgG is higher than IgM in pregnant women and HIV/AIDS patients (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}).

In general, in this review a total of 4,030 individuals were included and analyzed. The pooled prevalence of toxoplasmosis in this review was 81.00% (95% CI = 69.10--89.78). The *Q* statistic and I~2~ (inconsistency) were Cochran Q = 1,233.145293 (df = 17, *P* \< 0.0001) and I~2~ (inconsistency) = 98.6% (95% CI = 98.5%--98.8%) ([Figure 2](#fig2){ref-type="fig"}). In this meta-analysis and systematic review, time interval sub-group analysis was performed to observe *T. gondii* sero-prevalence change from old studies to recent studies. Included studies from 2009 to 2017 were grouped in five years\' interval. The pooled sero-prevalence of *T. gondii* from 2009 to 2013 was 90% (95% CI = 82%--96%) while it was 76% (95% CI = 61%--89%) in recent studies (2014--2017). Majority of the studies were conducted in recent years (2014--2017). Sub group analysis showed the sero-prevalence of *T. gondi* is decreased in recent years.

Sub-group analysis showed that 2,557 pregnant women were included and evaluated. Random effect analysis was used due to the heterogeneity between studies. The *Q* statistic and the pooled sero-prevalence were Cochran Q = 845.808548 (df = 8, *P* \< 0.0001) and 71.2 (95% CI = \[51.9%, 87.1%\] respectively ([Figure 3](#fig3){ref-type="fig"}). I~2~ (inconsistency) = 99.1% (95% CI = \[98.9%, 99.2%\] ([Figure 3](#fig3){ref-type="fig"}).

In HIV/AIDS *patients*, 1,473 individuals were included and evaluated. The *Q* statistic and the pooled seroprevalence were Cochran Q = 136.254836 (df = 8, *P* \< 0.0001) and 88.45 (95% CI = 80.87%--94.31%) respectively. I~2~ (inconsistency) = 94.1% (95% CI = 91.5%--95.7%) ([Figure 4](#fig4){ref-type="fig"}).

Begg and Egger tests were used for evaluating publication bias. Significant publication bias was not revealed in studies included about pregnant women (*P*-value \>0.05). There was significant bias among studies included about HIV/AIDS patients (*P*-value \>0.05).

4. Discussion {#sec4}
=============

*Toxoplasma gondii* infection is usually asymptomatic in immune-competent individuals or causes a mild illness \[[@B4]\]. However, it may become severe and can occasionally be fatal in immune-compromised people, such as HIV/AIDS patients or pregnant women \[[@B2], [@B6]\].

This is the first systematic review and meta-analysis of toxoplasmosis in pregnant women and HIV/AIDS patients in Ethiopia. Among 2,557 pregnant women in Ethiopia, the sero-prevalence of *T. gondii* was 71.1%. Furthermore, the seroprevalence of *T. gondii* in 1,473 HIV/AIDS patients was 88.45%. Immune compromised patients are at high risk of toxoplasmosis reactivation \[[@B17]\]. The finding of this meta-analysis showed that the seroprevalence of *T. gondii* in pregnant women and HIV/AIDS patients was higher than 70%, and there is a risk of reactivation of *T.gondii* in this group of population. Toxoplasmosis is an opportunistic disease that can cause very severe illness and fatality in immune compromised individuals. Pregnant women and HIV/AIDS patients are immune deficient individuals. This immune inefficiency could be the main risk factor for the higher sero-prevalence of *T. gondii*.

Toxoplasmosis is mainly transmitted to human by ingestion of oocysts with contaminated food and drinks, by consumption raw or undercooked meat contain bradyzoites. It can also be transmitted during blood transfusion and organ transplantation.

Immunocompromised patients are highly vulnerable groups for toxoplasmosis infection due to debilitated immune system.

In Ethiopia, human toxoplasmosis infection is a neglected disease \[[@B7]\]. Some studies were conducted on the seroprevalence of toxoplasmosis. The study group of majority of the studies was on pregnant women, general population, and HIV/AIDS patients. Toxoplasmosis in this group of the population can have devastating consequences. For instance, congenitally transmitted toxoplasmosis in pregnant women can have serious disease in fetus including chorioretinitis and neurological complications. In HIV/AIDS patients beside the virus toxoplasmosis may play a role in immune suppression and fasten the onset of AIDS symptoms.

Serological tests are considered as the gold standard in the diagnosis of *T. gondii* infection. Due to some shortcomings in serologic tests and the variation of serologic methods used, the seroprevalence of *T. gondii* infection might be varied.

In Ethiopia, *T. gondii* seroprevalence studies in pregnant women and HIV/AIDS mainly used latex agglutination test and Enzyme linked immune sorbent assay (ELISA) methods for diagnosis. The highest prevalence of toxoplasmosis was observed in individuals diagnosed with ELISA. For instance, in HIV/AIDS patients, 96.70% sero-prevalence of *T. gondii* was observed using ELISA. The incidence and prevalence of *T. gondii* infection varies depending on geographic areas, weather conditions, and age groups in Ethiopia.In Ethiopia, a review studied on the sero-prevalence of *T. gondii* in general population revealed the overall pooled prevalence was 74.73% \[[@B18]\]. The seropositivity in pregnant women and HIV/AIDS patients in the present study was 71.1% and 88.45%, respectively. The seroprevalence in HIV/AIDS patients was higher than reported from general population and pregnant women sero-prevelence in the present study.

5. Conclusions {#sec5}
==============

As far as we know and our literature search, this is the first systematic review and meta-analysis that provides information about the seroprevalence of *T. gondii* in pregnant women and HIV/AIDS patients in Ethiopia. Our finding indicates that researchers must give attention to the seroprevalence of toxoplasmosis in immunocompromised patients especially in HIV/AIDS patients, and pregnant women. Scaling up prevention and control methods and mainly strengthening educational efforts are necessary to avoid reactivation and to stop the spread of *T. gondii* infection.
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###### 

The baseline characteristics of the studies included in this literature search.

  Author        Publication Year   Study area                            Study group         No of cases   Total sample size   Sero-prevalence   Age range   Serologic test   Ref
  ------------- ------------------ ------------------------------------- ------------------- ------------- ------------------- ----------------- ----------- ---------------- ------------
  Shimelis T.   2009               Addis Ababa                           HIV/AIDS patients   154           165                 93.3%             20--66      ELISA            \[[@B8]\]
  Zemene E.     2012               Jimma town                            Pregnant women      168           201                 83.6%             17--35      ELISA            \[[@B3]\]
  Walle F.      2013               Bahir Dar                             HIV/AIDS patients   101           103                 87.4%             NA          ELISA            \[[@B9]\]
  Alem H.       2013               Addis Ababa (Tikur Anbesa Hospital)   HIV/AIDS patients   141           150                 94.0%             NA          ELISA            \[[@B10]\]
  Endris M.     2013               University of Gondar Hospital         HIV/AIDS patients   130           170                 76.5%             NA          LAT              \[[@B6]\]
  Hailu A.      2014               Ethiopia selected areas               HIV/AIDS patients   178           190                 93.6%             NA          ELISA            \[[@B11]\]
  Yohanes T.    2014               Arba Minch Hospital                   HIV/AIDS patients   150           170                 88.2%             NA          ELISA            \[[@B12]\]
  Hailu A.      2014               Ethiopia selected areas               Pregnant women      256           293                 87.3%             NA          ELISA            \[[@B11]\]
  Endris M.     2014               University of Gondar Hospital         Pregnant women      341           385                 88.6%             NA          LAT              \[[@B6]\]
  Gelaye W.     2015               Addis Ababa                           Pregnant women      246           288                 85.4%             18--42      LAT              \[[@B4]\]
  Awoke K.      2015               Felegehiwot Hospital, Bahir dar       Pregnant women      71            384                 18.5%             NA          LAT              \[[@B5]\]
  Agmas B.      2015               Debre Tabor Hospital                  Pregnant women      180           263                 68.4%             18--44      LAT              \[[@B1]\]
  Mohammed K.   2015               Mettu Karl Hospital                   HIV/AIDS patients   72            120                 60.0%             NA          LAT              \[[@B13]\]
  Abamecha F.   2016               Mizan Aman Hospital                   Pregnant women      198           232                 85.3%             NA          ELISA            \[[@B7]\]
  Tegegne D.    2016               Agaro town                            HIV/AIDS patients   109           135                 80.7%             NA          LAT              \[[@B14]\]
  Negero J.     2017               Bonga Hospital                        Pregnant women      159           210                 75.7%             15--44      LAT              \[[@B15]\]
  Negussie A.   2017               Jigjiga Hospital                      Pregnant women      105           301                 34.9%             NA          LAT              \[[@B2]\]
  Jejaw A.      2017               Mizan Aman Hospital                   HIV/AIDS patients   261           270                 96.7%             18--49      ELISA            \[[@B16]\]

NA: not applicable.

###### 

Baseline characteristics of included studies (based on IgG assessment).

  Author        Publication year   Study area                          Study group         No of cases   sample size   IgG cases   Sero-prevalence   Age range   Serologic test   Ref
  ------------- ------------------ ----------------------------------- ------------------- ------------- ------------- ----------- ----------------- ----------- ---------------- ------------
  Zemene E.     2012               Jimma town                          Pregnant women      168           201           163         97.0%             17--35      ELISA            \[[@B3]\]
  Walle F.      2013               Bahir Dar                           HIV/AIDS patients   101           103           90          89.1%             NA          ELISA            \[[@B9]\]
  Alem H.       2013               Addis Ababa Tikur Anbesa Hospital   HIV/AIDS patients   141           150           141         100.0%            NA          ELISA            \[[@B10]\]
  Hailu A.      2014               Ethiopia selected areas             Pregnant women      256           293           247         96.5%             NA          ELISA            \[[@B11]\]
  Endris M.     2014               University of Gondar Hospital       Pregnant women      341           385           341         100.0%            NA          LAT              \[[@B6]\]
  Hailu A.      2014               Ethiopia selected areas             HIV/AIDS patients   178           190           172         96.6%             NA          ELISA            \[[@B11]\]
  Abamecha F.   2016               Mizan Aman Hospital                 Pregnant women      198           232           191         96.5%             NA          ELISA            \[[@B7]\]
  Jejaw A.      2017               Mizan Aman Hospital                 HIV/AIDS patients   261           270           255         97.7%             18--49      ELISA            \[[@B16]\]

NA: not applicable.

###### 

Baseline characteristics of included studies (based on IgM assessment).

  Author        Publication year   Study area                Study group         No of cases   Sample size   IgM positive   Sero-prevalence   Age range   Serologic test   Ref
  ------------- ------------------ ------------------------- ------------------- ------------- ------------- -------------- ----------------- ----------- ---------------- ------------
  Zemene E.     2012               Jimma town                Pregnant women      168           201           2              1.2               17--35      ELISA            \[[@B3]\]
  Walle F.      2013               Bahir dar                 HIV/AIDS patients   101           103           11             10.89             NA          ELISA            \[[@B9]\]
  Hailu A.      2014               Ethiopia selected areas   Pregnant women      256           293           9              3.52              NA          ELISA            \[[@B11]\]
  Hailu A.      2014               Ethiopia selected areas   HIV/AIDS patients   178           190           6              3.37              NA          ELISA            \[[@B11]\]
  Abamecha F.   2016               Mizan Aman Hospital       Pregnant women      198           232           7              3.54              NA          ELISA            \[[@B7]\]
  Jejaw A.      2017               Mizan Aman Hospital       HIV/AIDS patients   261           270           6              2.3               18--49      ELISA            \[[@B16]\]

NA: not applicable.

[^1]: Academic Editor: Bernard Marchand
